Biography and Research Information
OverviewAI-generated summary
Shayu Deshpande's research focuses on understanding the molecular mechanisms underlying multiple myeloma and developing strategies for improved hearing healthcare access in underserved populations. His work on multiple myeloma investigates its molecular makeup, evolutionary pathways, and the role of the immune microenvironment in disease progression from initial diagnosis to relapse-refractory states. Deshpande has also led the development and protocol design for hybrid effectiveness-implementation studies examining school-based enhanced hearing screening and telehealth follow-up for children in rural Alaska (North STAR trial) and rural Kentucky (Appalachian STAR Trial). These initiatives aim to transform access to specialty care by leveraging technology for children in remote areas.
Deshpande's scholarship metrics include an h-index of 15, 46 total publications, and 1,010 total citations. He has established collaborations with several colleagues at the University of Arkansas for Medical Sciences, including Michael Bauer, Christopher P. Wardell, Susan D. Emmett, and Samantha Kleindienst Robler, with whom he has co-authored multiple publications.
Metrics
- h-index: 15
- Publications: 46
- Citations: 1,037
Selected Publications
-
Transforming Access to Hearing Care: Community Perspectives on School-Based Telehealth in Rural Appalachia (2025)
-
School-based enhanced hearing screening and specialty telehealth follow-up for hearing loss among children in rural Alaska: study protocol for a hybrid effectiveness-implementation stepped wedge, cluster-randomized controlled trial (North STAR trial) (2025)
-
School-Based Enhanced Hearing Screening and Specialty Telehealth Follow-Up for Hearing Loss Among Children in Rural Alaska: Study Protocol for a Hybrid Effectiveness-Implementation Stepped Wedge, Cluster-Randomized Controlled Trial (North STAR Trial) (2025)
-
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level (2022)
-
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states (2022)
-
Interaction of the Class A Scavenger Receptor with Multiple Myeloma Cells (2022)
-
The Spatio-Temporal Evolution of Multiple Myeloma from Baseline to Relapse-Refractory States (2022)
-
The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma (2021)
Collaboration Network
Top Collaborators
Michael Bauer
8 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- The Spatio-Temporal Evolution of Multiple Myeloma from Baseline to Relapse-Refractory States
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
Showing 5 of 8 shared publications
Sharmilan Thanendrarajan
8 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- The Spatio-Temporal Evolution of Multiple Myeloma from Baseline to Relapse-Refractory States
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
Showing 5 of 8 shared publications
Maurizio Zangari
8 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- The Spatio-Temporal Evolution of Multiple Myeloma from Baseline to Relapse-Refractory States
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
Showing 5 of 8 shared publications
Frits van Rhee
8 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- The Spatio-Temporal Evolution of Multiple Myeloma from Baseline to Relapse-Refractory States
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
Showing 5 of 8 shared publications
Carolina Schinke
8 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- The Spatio-Temporal Evolution of Multiple Myeloma from Baseline to Relapse-Refractory States
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
Showing 5 of 8 shared publications
Faith E. Davies
NYU Langone Health (US)
8 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- The Spatio-Temporal Evolution of Multiple Myeloma from Baseline to Relapse-Refractory States
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
Showing 5 of 8 shared publications
Cody Ashby
7 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- The Spatio-Temporal Evolution of Multiple Myeloma from Baseline to Relapse-Refractory States
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
- Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
Showing 5 of 7 shared publications
Bart Barlogie
Hôpital Claude Huriez
7 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
- The Spatio-Temporal Evolution of Multiple Myeloma from Baseline to Relapse-Refractory States
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
- Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
Showing 5 of 7 shared publications
Eileen M. Boyle
Centre National de la Recherche Scientifique (FR)
5 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
- Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
- Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
Ruslana G. Tytarenko
5 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
- Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
- Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
Christopher P. Wardell
5 shared publications
In database
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
- Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
- Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
Thierry Façon
Hôpital Claude Huriez (FR)
5 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
- Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
- Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
Charles Dumontet
Centre de Recherche en Cancérologie de Lyon (FR)
5 shared publications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
- Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
- Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
Samantha Kleindienst Robler
University of Arkansas for Medical Sciences
5 shared publications
In database
- School-based enhanced hearing screening and specialty telehealth follow-up for hearing loss among children in rural Alaska: study protocol for a hybrid effectiveness-implementation stepped wedge, cluster-randomized controlled trial (North STAR trial)
- School-Based Enhanced Hearing Screening and Specialty Telehealth Follow-Up for Hearing Loss Among Children in Rural Alaska: Study Protocol for a Hybrid Effectiveness-Implementation Stepped Wedge, Cluster-Randomized Controlled Trial (North STAR Trial)
- Improving Access to Specialty Care for Rural Children Using Enhanced Hearing Screening and Specialty Telehealth Follow-Up in Rural Kentucky Schools: Protocol for a Hybrid Effectiveness-Implementation Stepped Wedge, Cluster-Randomized Controlled Trial (Appalachian STAR Trial) (Preprint)
- Improving Access to Specialty Care for Rural Children Using Enhanced Hearing Screening and Specialty Telehealth Follow-Up in Rural Kentucky Schools: Protocol for a Hybrid Effectiveness-Implementation Stepped Wedge, Cluster-Randomized Controlled Trial (Appalachian STAR Trial)
- Transforming Access to Hearing Care: Community Perspectives on School-Based Telehealth in Rural Appalachia
Janet Prvu Bettger
Duke University Hospital
5 shared publications
In database
- School-based enhanced hearing screening and specialty telehealth follow-up for hearing loss among children in rural Alaska: study protocol for a hybrid effectiveness-implementation stepped wedge, cluster-randomized controlled trial (North STAR trial)
- School-Based Enhanced Hearing Screening and Specialty Telehealth Follow-Up for Hearing Loss Among Children in Rural Alaska: Study Protocol for a Hybrid Effectiveness-Implementation Stepped Wedge, Cluster-Randomized Controlled Trial (North STAR Trial)
- Improving Access to Specialty Care for Rural Children Using Enhanced Hearing Screening and Specialty Telehealth Follow-Up in Rural Kentucky Schools: Protocol for a Hybrid Effectiveness-Implementation Stepped Wedge, Cluster-Randomized Controlled Trial (Appalachian STAR Trial) (Preprint)
- Improving Access to Specialty Care for Rural Children Using Enhanced Hearing Screening and Specialty Telehealth Follow-Up in Rural Kentucky Schools: Protocol for a Hybrid Effectiveness-Implementation Stepped Wedge, Cluster-Randomized Controlled Trial (Appalachian STAR Trial)
- Transforming Access to Hearing Care: Community Perspectives on School-Based Telehealth in Rural Appalachia
Similar Researchers
Based on overlapping research topics
Phillip Farmer
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Telemedicine and Telehealth Implementation
Health Disparities and Outcomes
Manuel Heredia
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Health Disparities and Outcomes
Cancer-related molecular mechanisms research
Manozna Karri
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Telemedicine and Telehealth Implementation
Health Disparities and Outcomes
Amy Schexnayder
University of Arkansas for Medical Sciences
Telemedicine and Telehealth Implementation
Health Disparities and Outcomes
Child and Adolescent Health
Guido Tricot
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Health Disparities and Outcomes
Cancer-related molecular mechanisms research
Kristin Sarah Bogda
University of Arkansas at Fayetteville
Health Disparities and Outcomes
Cancer-related molecular mechanisms research
Child and Adolescent Health